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Abstract
Background: Graft-versus-host disease (GVHD) remains the main barrier to broader application of allogeneic hematopoietic
stem cell transplantation (alloSCT) as a curative therapy for host malignancy. GVHD is mediated by allogeneic T cells
directed against histocompatibility antigens expressed by host tissues. Based on previous studies, we postulated that the
integrin CD103 is required for CD8-mediated GVHD, but not for graft-versus-tumor effects (GVT).
Methodology/Principal Findings: We herein provide evidence in support of this hypothesis. To circumvent the potentially
confounding influence of donor CD4 T cells, we developed an alloSCT model in which GVHD mortality is mediated by
purified CD8 T cells. In this model, host-reactive CD8 T cells receive CD4 T cell help at the time of initial activation but not in
the effector phase in which mature CD8 T effectors migrate into host tissues. We show that donor CD8 T cells from wild-
type BALB/c mice primed to host alloantigens induce GVHD pathology and eliminate tumors of host origin in the absence
of host CD4 T cells. Importantly, CD103 deficiency dramatically attenuated GVHD mortality, but had no detectable impact
on the capacity to eliminate a tumor line of host origin. We provide evidence that CD103 is required for accumulation of
donor CD8 T cells in the host intestinal epithelium but not in the tumor or host lymphoid compartments. Consistent with
these data, CD103 was preferentially expressed by CD8 T cells infiltrating the host intestinal epithelium but not by those
infiltrating the tumor, lamina propria, or lymphoid compartments. We further demonstrate that CD103 expression is not
required for classic CD8 effector activities including cytokine production and cytotoxicity.
Conclusions/Significance: These data indicate that CD103 deficiency inhibits GVHD pathology while sparing anti-tumor
effects mediated by CD8 T cells, identifying CD103 blockade as an improved strategy for GVHD prophylaxis.
Citation: Liu K, Anthony BA, Yearsly MM, Hamadani M, Gaughan A, et al. (2011) CD103 Deficiency Prevents Graft-versus-Host Disease but Spares Graft-versus-
Tumor Effects Mediated by Alloreactive CD8 T Cells. PLoS ONE 6(7): e21968. doi:10.1371/journal.pone.0021968
Editor: Ryan M. Teague, Saint Louis University, United States of America
Received February 7, 2011; Accepted June 14, 2011; Published July 14, 2011
Copyright:  2011 Liu et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted
use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was funded by the National Institutes of Health, grant number: RO1 AI36532. The funders had no role in study design, data collection and
analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: gregg.hadley@osumc.edu
. These authors contributed equally to this work.
Introduction
The potential of allogeneic hematopoietic stem cell transplanta-
tion (alloSCT) to eliminate host malignancy is limited due to graft-
versus-host disease (GVHD) mediated by donor T cells[1].
Although multiple means exist to neutralize donor-reactive T cells,
such strategies also inhibit anti-tumor effects (GVT), leaving the host
vulnerable to disease relapse [2]. CD8 T cells are important
mediators of acute GVHD and GVT effects following alloSCT due
to their capacity to cross-react at high frequency with polymorphic
variants of MHC class I molecules [3], and recognize polymorphic
peptides derived from non-MHC proteins (i.e., minor H antigens) in
the context of self MHC class I molecules [4]. Thus, even MHC-
matched transplants elicit potent immune responses mediated by
donor CD8 T cells. Moreover, CD8 T effectors elicited in response
to host alloantigens possess diverse effector pathways for destruction
of host cells. Ubiquitous expression of MHC I molecules assures that
all host cell-types are potentially susceptible to CD8-mediated
injury. The relevance of these data to clinical events is supported by
studies showing that depletion of CD8 cells from the alloSCT
inoculum attenuates GVHD episodes [5,6] in the human system.
We have previously reported that the expression of the integrin
CD103 by CD8 T effector populations is required for develop-
ment of intestinal GVHD pathology and associated mortality
following alloSCT [7]. The known ligand for CD103 (E-cadherin)
is generally lost by epithelial tumors during transition to invasive
carcinoma [8], yet most tumor cells retain high level expression of
LFA-1 ligands, such as ICAM-1[9]. Le Floc’h et al. [10] have
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reported that tumor-reactive CTL clones use LFA-1-dependent
interactions for tumor lysis when CD103/E-cadherin interactions
are not available. These data raised the possibility that CD103
expression is required for GVHD pathology but is dispensable for
effective anti-tumor immunity mediated by donor CD8 T cells.
The goal of the present study was to test the hypothesis that
CD103 deficiency can prevent GVHD pathology without
compromising tumor immunity mediated by alloreactive CD8 T
cells. We herein provide evidence in support of this hypothesis,
and document that this reflects a requirement for CD103 in
accumulation of CD8 T cells in epithelial but not non-epithelial
host compartments. That these data provide novel insight into
more effective strategies for GVHD prophylaxis is discussed.
Results
CD103 deficiency attenuates intestinal GVHD mediated
by donor CD8 T cells
To assess the impact of CD103 on GVHD and GVT effects
mediated by donor CD8 T cells, we used an MHC-mismatched
model (BALB/c-to-A/J, disparate at H-2Kk, H-2Ak, and H-2Ek)
to take advantage of the high frequency of CD8 T cells directed to
mismatched MHC I alloantigens [3]. To exclude confounding
pathology mediated by donor CD4 T cells, CD8 T cells from
BALB/c-WT (WT) or BALB/c-CD103 KO mice were purified
and adoptively transferred into lethally irradiated A/J mice.
Donor mice were primed to host alloantigens prior to transfer to
circumvent the well documented requirement for CD4 T cell help
in eliciting CD8-dependent GVHD [11]. Thus, host-reactive CD8
T cells in this model received CD4 T cell help at the time of initial
activation but not in the effector phase in which mature CD8 T
effectors migrate into host tissues.
As shown in Fig. 1A, purified CD8 T cells from primed WT
donors (,1% CD4 T cells) induced GVHD onset as early as day 6
post transfer resulting in 75% (9/12) GVHD mortality within 90
days. In contrast, purified CD8 T cells from KO donors elicited
milder or undetectable GVHD resulting in a significantly lower
incidence of GVHD mortality (23%; n = 3/13, log-rank p-
value = 0.003). Recipients of WT CD8 T cells (WT recipients)
Figure 1. CD103 deficiency attenuates intestinal GVHDmediated by donor CD8 T cells. CD8 T cells primed to A/J alloantigens from either
BALB/c-WT (WT) or BALB/c-CD103 KO donors were adoptively transferred into lethally irradiated A/J recipient mice in combination with WT BMC. A.
Data shown are survival rates of irradiation control mice (diamonds), recipients of WT BMC plus purified CD8 T cells from either WT (WT CD8, squares,
n = 12) or KO donors (KO CD8, triangles, n = 13), and recipients of BMC only (circles, n = 3). These data derive from two separate experiments with
similar results. **p-value= 0.003, compared to the survival of hosts receiving WT CD8 T cells (log-rank test). B. H&E sections of the host intestine
(upper panel) and spleen (lower panel) taken from recipients of WT or KO CD8 T cells. Arrows indicate apoptotic bodies. C. Mean number of apoptotic
bodies per hundred intestinal villi 6 SEM in recipients of CD8 T cells from WT donors (WT, closed bar, n = 3) or KO donors (KO, open bar, n = 3).
**p,0.01.
doi:10.1371/journal.pone.0021968.g001
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also experienced greater weight loss compared to recipients of KO
CD8 T cells (data not shown).
Recipient mice were sacrificed at day 12 post-transfer for
histologic analyses, a time at which more than half of the recipients
of WT CD8 T cells had died of GVHD (Fig. 1A). At this time
point, approximately 40% of WT CD8 T cells infiltrating the host
intestinal epithelium but not the host spleen expressed significant
levels of CD103 (Figure S1). As shown in Figure 1C, significantly
higher numbers of apoptotic bodies were present in the intestinal
epithelium of recipients of WT CD8 T cells (6166.0/100 villi)
compared to those receiving CD103 KO CD8 T cells (1363.5/
100 villi)(mean 6 SEM). Note the absence of apparent differences
between WT and CD103 KO cells in pathology elicited in the host
spleen (Figure 1B), despite the presence of obvious injury at this
site. These data are consistent with a role for CD103 in promoting
injury to the host intestinal epithelium mediated by CD8 T cells.
CD103 is not required for effective clearance of solid
tumor by donor CD8 T cells
To determine whether CD103 deficiency compromises GVT
effects mediated by CD8 T cells in this model, primed CD8 T cells
from WT or KO donors were transferred into lethally-irradiated
A/J mice together with the A/J background fibrosarcoma, SaI/N.
A control group of A/J mice received BMC and SaI/N cells
without donor CD8 T cells. As shown in Fig. 2A, tumor growth
was detected in all mice transferred with BMC alone within 2
weeks with the majority (5/6) exhibiting massive tumor growth by
day 21 post-transfer. In marked contrast, the majority of recipients
of WT CD8 T cells (6/8) died of GVHD by day 14 before any
detectable tumor growth as compared to 2/8 recipients of KO
CD8 T cells (data not shown). Fig. 2A shows that WT and KO
CD8 T cells both effectively inhibited tumor growth as reflected by
a nearly 20-fold reduction in tumor volume compared to mice
receiving donor BMC without CD8 T cells at day 21 post transfer.
These data suggested that CD103 expression is not required for
GVT effects mediated by donor CD8 T cells.
Given that the majority of recipients of WT CD8 T cells died
from GVHD pathology before detection of tumor growth, we
could not directly compare GVT effects mediated by WT vs. KO
CD8 T cells in this model. To circumvent this problem, we
transferred primed CD8 T cells from either WT or KO donors
into syngeneic BALB.scid mice together with SaI/N tumor cells.
Thus, the hosts are syngeneic to the donor T cells in this model,
allowing an evaluation of GVT effects mediated by alloreactive
CD8 T cells without the confounding occurrence of GVHD
pathology. As shown in Fig. 2B, all mice receiving tumor alone
died within 35 days, whereas recipients of CD8 T cells from either
WT or KO donors survived for .70 days without detection of
tumor growth. Thus, these data indicated that CD103 deficiency
does not significantly compromise GVT effects mediated by donor
CD8 T cells in this model.
CD103 expression is not required for accumulation of
donor CD8 T effectors in the tumor
The SaI/N tumor line –similar to most human tumors [8] - does
not express detectable levels of E-cadherin (data not shown). We
therefore postulated that separation of GVHD and GVT effects by
CD103 deficiency reflects a lack of requirement for CD103
expression for efficient accumulation of donor CD8 T cells in the
tumor and other non-epithelial compartments. To test this
hypothesis, an equal mixture of CD8 T cells from WT (Thy1.1)
and KO (Thy1.2) donors were transferred in combination with WT
BMCs (Thy1.1) into lethally-irradiated A/J hosts together with SaI/
N tumor cells. Note that the donors were marked with Thy1 alleles
to facilitate identification of the WT or KO origin of CD8 T cells,
and that sublethal doses of CD8 T cells were transferred in these
experiments to extend host survival. Recipient mice were sacrificed
at days 7, 14, 21 and 28, and lymphocytes isolated from host tissues
were subjected to flow cytometry. Consistent with our prior study
[7], WT CD8 T cells rapidly outnumbered KO CD8 T cells in the
host intestinal epithelium by the third week post transfer (Fig. 3A).
In contrast, comparable numbers of WT and KO CD8 T cells
accumulated in the tumor (Fig. 3A). Fig. 4A shows that CD103
expression by WT CD8 T cells infiltrating the host intestinal
epithelium progressively increased from 66% at day 14 to 91% at
Figure 2. CD103 is not required for effective clearance of solid
tumor by donor CD8 T cells. A. Lethally irradiated A/J mice were
inoculated with SaI/N fibrosarcoma (H-2a) plus BALB/c-WT (WT) either
alone (BMC only, n = 6) or in combination with purified CD8 T cells from
primed WT (n= 8) or BALB/c-CD103 KO donors (n = 8). Data shown are
the mean volumes of solid tumor (cm3) measured at the indicated time
points 6 SEM. N.D. indicates that no tumor was detected. This is a
combination of two separate experiments with similar results. Since
some experimental mice died early of GVHD, data of 6, 5 or 2 recipient
mice of each respective group are shown in last time point. B. Sal/N
fibrosarcoma cells (1.06106) were transferred into BALB.scid mice alone
(closed circles; n = 4) or together with primed CD8 T cells (1.06107) from
either WT (triangles; n = 4) or KO donors (open circles; n = 4). Data show
mortality of recipient mice. Surviving mice were sacrificed at day 70
after adoptive transfer.
doi:10.1371/journal.pone.0021968.g002
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day 28 post adoptive transfer. In contrast, tumor-infiltrating CD8 T
cells of WT origin expressed negligible levels of CD103 at all time
points (Fig. 4B), consistent with a lack of involvement of the CD103
pathway in tumor elimination by donor CD8 T cells. Fig. 5 shows
preferential accumulation of WT CD8 T cells in the host intestinal
epithelium but not in a variety of non-epithelial compartments
including the LP, PP, and MLN, despite high level CD103
expression by WT CD8 T cells in the latter compartments (data not
shown). These data indicate that CD103 deficiency prevents
accumulation of donor CD8 T cells in host epithelial compartments
without compromising their capacity to accumulate in non-
epithelial compartments, which includes both lymphoid tissues
and the tumor itself.
CD8 T effector function is not attenuated by CD103
deficiency
Cytokines produced by CD8 T cells during GVHD responses -
particularly IFN-c, IL-2 and TNF-a - likely play critical roles in
promoting GVT effects (1). As shown in Fig. 6, CD8 T cells
infiltrating the host intestinal epithelium produced copious
amounts of the three cytokines at days 7, independently of their
capacity to express CD103. As shown in Figure S2, primed CD8 T
cells from KO donors were just as effective as those from primed
WT donors in eliminating cells of host origin in vivo. Thus, these
data indicate that CD103 expression by CD8 T cells is not
required for acquisition of classic effector function by CD8 T cells
activated during the course of GVHD.
Discussion
The salient finding of the present study is that CD103 deficiency
prevents GVHD mortality mediated by donor CD8 T cells
without compromising their capacity to eliminate tumors of host
origin. We have previously documented a key role for CD103 in
promoting intestinal GVHD pathology mediated by CD8 T cells
[7]. The present data extend the prior studies by showing that
CD103 blockade does not abrogate the capacity of donor CD8 T
cells to eliminate allogeneic tumors. These data identify the
CD103 pathway as being critical to GVHD pathology, yet
dispensable for host defense against malignancy. It will now be
Figure 3. CD103 expression is not required for accumulation of donor CD8 T effectors at the site of tumor growth. Equal numbers of
CD8 T cells from BALB/c-WT (WT, Thy1.1+) and BALB/c-CD103 KO, (KO, Thy1.1+Thy1.2+) donors were adoptively transferred into a group of lethally
irradiated A/J mice together with BALB/c-WT BMC plus SaI/N tumor cells. Recipient mice were sacrificed at days 7, 14, 21 and 28. Lymphocytes
isolated from the host intestinal epithelium and the tumor were subjected to flow cytometric analyses. A. Representative dot plots of Thy1.2
expression by gated CD8 T cells in the two compartments at the indicated time points. B. Mean ratios 6 SEM (n= 5) of WT versus KO CD8 T cells in
the intestinal epithelim (IEL, solid circles) and tumor (TIL, open circles). *p,0.05 compared with TIL.
doi:10.1371/journal.pone.0021968.g003
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Figure 4. CD103 is preferentially expressed by CD8 T cells in the intestinal epithelium as compared to the tumor. Equal numbers of
CD8 T cells from BALB/c-WT (WT, Thy1.1+) and BALB/c-CD103 KO (KO, Thy1.1+Thy1.2+) donors were adoptively transferred into a group of lethally
irradiated A/J mice together with BALB/c-WT BMC plus SaI/N tumor cells. Recipient mice were sacrificed at days 7, 14, 21 and 28. Lymphocytes
isolated from the indicated host compartments were then subjected to flow cytometric analyses. A. Mean percentage 6 SEM (n= 5) of CD8 T cells in
the intestinal epithelium (IEL closed circles) and the tumor (open circles) that expressed significant levels of CD103 at the indicated time points. B.
Representative dotplot of CD103 expression by gated CD8+ cells in the intestinal epithelium (IEL) and tumor (TIL).
doi:10.1371/journal.pone.0021968.g004
Figure 5. CD103 is not required for accumulation of CD8 T cells in the lamina propria or mucosal lymphoid compartments during
GVHD. Equal numbers of CD8 T cells from BALB/c-WT (WT, Thy1.1+) and BALB/c-CD103 KO (KO, Thy1.1+Thy1.2+) donors were adoptively transferred
into a group of lethally irradiated A/J mice together with BALB/c-WT BMC plus SaI/N tumor cells. Recipient mice were sacrificed at day 21.
Lymphocytes isolated from the indicated host compartments were subjected to flow cytometric analyses. A. Representative dot plots of WT and KO
CD8 T cells in the host intestinal epithelium (IEL), lamina propria (LPL), Peyer’s patch (PPL), and mesenteric lymph node (MLN) at d21 post alloSCT. B.
Mean ratios 6 SEM (n= 5) of WT to KO CD8 T cells in the indicated compartments. *p,0.05 compared with IEL; **p-value,0.01 compared with IEL.
doi:10.1371/journal.pone.0021968.g005
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important to extend these findings to spontaneously developing
tumors in the human system. As the most common application of
alloSCT is to treat hematopoietic malignancy[1], it will be
particularly important to confirm relevance to anti-leukemia
effects.
We have previously documented a key role for TGFb in
accumulation of donor CD8 T cells within the host intestinal
epithelium during GVHD [7]. The present findings document that
CD103 expression is not required for efficient circulation of CD8 T
cells through host lymphoid tissues and other non-epithelial sites
including the tumor itself (Fig.5). These data are consistent with a
model in which host-reactive CD8 T cells entering host epithelial
compartments following alloSCT are induced to express CD103 by
bioactive TGFb, a cytokine known to promote CD103 expression
by CD8 T cells[12] and which is ubiquitous at GVHD target sites
such as the gut epithelium [13]. In this model, CD103 expression
promotes accumulation of donor CD8 T cells in host tissues via
interaction with E-cadherin, which is highly and specifically
expressed by cells comprising host epithelial compartments [14]
Our data indicate that CD8 T cells unable to express CD103
remain capable of exerting anti-tumor effects – likely through LFA-
1-dependent mechanisms[10] - hence providing a mechanistic basis
for the separation of GVHD and GVT effects by CD103 disruption.
That some recipients (,25%) of KO CD8 T cells succumb to
GVHD mortality (Fig. 1) is consistent with our data showing that
CD103-deficient CD8 T cells retain the capacity to accumulate in
non-epithelial compartments of the host independently of CD103
expression. These data are in accord with observations that tumor-
reactive CTL clones utilize LFA-1-dependent interactions as an
alternative pathway to promote directed release of cytotoxic
granules in lieu of CD103/E-cedherin interactions [10], and
migrate to cognate tumor independently of CD103 expression
[15].
CD8 T cells have great potential as a means to cure human
malignancy but this approach is currently limited by the
propensity of these cells to mediate GVHD pathology. Indeed,
both alloSCT [5,6] and delayed leukocyte infusion [16] have the
capacity to cure malignancy but both are limited by concomitant
GVHD pathology. Multiple means exist to neutralize CD8 T cells
to prevent GVHD pathology but current approaches have the
potential to abrogate critical anti-tumor responses, and thus are
likely ineffectual in the long term. The present data provide proof-
of principle that CD103 blockade can prevent GVHD mortality
mediated by donor CD8 T cells without compromising GVT
effects, thus pointing to CD103 blockade as an inherently superior
means of GVHD prophylaxis. We have documented that reagents
that deplete CD103-expressing cells in vivo do not significantly
compromise T reg function [17], so this approach appears unlikely
to interfere with physiologic mechanisms for suppressing tumor
growth.
In summary, the present findings indicate that CD103
deficiency attenuates CD8-dependent GVHD pathology while
Figure 6. CD103 expression is not required for cytokine production by gut infiltrating CD8 T cells. Equal numbers of CD8 T cells from
BALB/c-WT (WT, Thy1.1+Thy1.2-) and BALB/c-CD103 KO donors (KO, Thy1.1+Thy1.2+) were adoptively transferred into a group (n = 3) of lethally
irradiated A/J mice together with WT BMC plus SaI/N tumor cells. Lymphocytes were isolated from the host intestinal epithelium at day 7 post-
transplant and subjected to intracellular staining for INFc, TNFa and IL-2. A. Representative histograms of cytokine staining by gated CD8+
lymphocytes of either WT or KO origin (thin line) vs. isotype control staining (heavy line). B. Mean production (6SEM) of the indicated cytokines by
gated WT (n= 3, solid bars) or KO CD8 T cells (n = 3, open bars). Data represent two independent experiments with similar results.
doi:10.1371/journal.pone.0021968.g006
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preserving beneficial GVT effects, and shed light on the
underlying mechanisms. It will now be important to determine if
CD103 depleting agents [17] provide a viable strategy for
separating GVHD and GVT effects in WT hosts.
Materials and Methods
Mice
Mice of strains C57BL/6 (B6), A/J, BALB/cJ (WT), C.129S2-
Itgaetm1Cmp/J, (KO) were purchased from the Jackson Laboratory
(Bar Harbor, ME). Colonies of WT and KO mice were expanded
from breeder stocks and maintained in house. CBy.Cg-Thy1a
Tg(TcraCl1,TcrbCl1)1Shrm/J (BALB/c-Thy1.1) mice were kind-
ly provided by Dr. Donna Farber. Thy1.1+Thy1.2+ CD103-
deficient mice were generated by interbreeding BALB/c-Thy1.1
and KO (Th1.2+) mice, followed by backcrossing of the F1
generation to the KO parental strain to generate Thy1.1+Thy1.2+
KO mice, identified by surface staining using mAbs to Thy1.1,
Thy1.2 and CD103. All mice were housed in specific pathogen-
free conditions in the animal facilities at the University of
Maryland, Baltimore, MD and The Ohio State University,
Columbus, OH. Animal studies were approved by University
Laboratory Animal Resources at The Ohio State University
(approval 2009A0213) and the Office of Animal Welfare
Assurance at the University of Maryland, Baltimore (approval
11-19-04).
Antibodies
Directly conjugated anti-mouse antibodies used included CD3-
FITC, CD8-FITC, CD8-PerCP, CD8-APC, Thy1.1-PerCP,
Thy1.2-PE, M290 (anti-CD103)-PE and FITC, IFN-c-PE, TNF-
a-PE, IL-2 and isotype-matched controls, all purchased from BD
Biosciences Pharmingen (San Diego, CA).
GVHD and GVT models
For CD8 T cell transfer experiments, lethally-irradiated (9 Gy,
137Cs -radiation, split into 2 doses) A/J hosts (H-2a) were
reconstituted within 4-6 hours with a single 0.5 ml intravenous
inoculum containing 1.06107 BALB/c-WT bone marrow cells
(BMC) and 1.06107 naı¨ve or alloantigen-primed CD8 T cells
from either BALB/c-WT or BALB/c-KO mice. Donor spleno-
cytes (SC) were enriched for CD8 T cells by treatment with mAbs
to CD4 (RL172.4), heat stable antigen (J11D) and I-Ed (14.4.4s),
followed by incubation in 1/10 Low-Tox M rabbit complement
(Accurate Chemical and Scientific, Westbury, NY). The resulting
cell suspensions contained ,1% CD4+ T cells. In some
experiments, recipient mice were also injected subcutaneously on
the back with 1.06106 A/J background fibroblast sarcoma (SaI/
N) tumor cells (kindly provided by Dr. Suzanne Ostrand-
Rosenberg). To determine the role of CD103 in CD8 T cell
accumulation in host tissue compartments, 26106 BALB/c-WT
(Thy1.2+) and 26106 BALB/c-KO CD8 cells (Thy1.1+Thy1.2+)
were transferred in combination with BALB/c-WT BMCs
(Thy1.2) into lethally-irradiated A/J hosts. Mice were randomly
grouped before and after irradiation. Control irradiated untreated
mice were also included in each experiment.In some experiments,
GVHD pathology was prevented by transfer of 1.06107
alloantigen-primed WT or KO CD8 T cells into syngeneic
BALB.scid mice together with SaI/N cells.
Host survival following alloSCT was monitored daily, and
GVHD severity was quantitated as described by Cooke et al. [18].
Briefly, recipient mice were scored for five parameters (weight loss,
skin integrity, fur texture, mobility, and posture) using a scale of 0–
2 (0 = normal, 1 = mildly abnormal, and 2 = severely abnormal).
The GVHD severity score was the sum of the scores for each
individual criterion. Death due to GVHD was defined by the
absence of tumor and the presence of clinical signs of GVHD.
GVT effects were assessed by monitoring tumor size every 2 days.
Death due to tumor was defined by the absence of GVHD and the
presence of measurable tumor. For histologic analyses, host organs
were harvested at the designated times, fixed in 10% phosphate-
buffered formalin, and embedded in paraffin. Sections (6 mm) were
stained with hematoxylin and eosin.
Flow cytometry
Lymphocytes infiltrating the intestinal epithelium and LP
during GVHD were isolated as previously described [7].
Lymphocytes were isolated from lymphoid organs by mincing
with forceps and passage through nylon mesh of 100-mm pore size.
Liver-infiltrating lymphocytes were harvested as previously descri-
bed [19]. To isolate tumor-infiltrating lymphocytes, the tumor and
the surrounding tissue within 1 mm were minced and the tumor
pieces were incubated with stirring at 37uC for 30 min in a
mixture of collagenase (Worthington Biochemical, Freehold, NJ),
soybean trypsin inhibitor (Sigma-Aldrich, St. Louis, MO), and
DNase (Roche, Indianapolis, IN). Host organ- and tumor-
infiltrating lymphocytes were isolated by centrifugation on Lymp-
holyte-M (Cedarlane Laboratories, Hornby, Ontario, Canada).
Lymphocyte populations were washed twice in FACS buffer prior
to antibody staining. Lymphocyte populations were stained and
analyzed as previously described [7]. Assays were performed
according to the manufacturer’s protocol.
In vivo cytotoxicity assay
A modification of the technique originally described by Oehen
and Brduscha-Riem [20] was adapted for use in these studies. In
brief, at day 7 after alloSCT, A/J recipients of CD8 T cells from WT
or KO donors were injected by tail vein with 2.06107 SC from WT
donors (donor-type) and 2.06107 SC from A/J donors (host-type).
SC were labeled with 0.5 mM or 5.0 mM CFSE (Invitrogen Corp.),
respectively, prior to transfer to generate cells distinguishable by flow
cytometry. Eighteen hours later, animals were bled and erythrocytes
were lysed using red blood cell lysing buffer (Sigma). The proportions
of CFSE-labeled host (low intensity) and donor cells (high intensity)
were determined by flow cytometry (BD Biosciences Pharmingen,
San Diego, CA) and an in vivo cytotoxicity index (measuring the in
vivo cytotoxic response to host-type targets) was computed as the
percentage of remaining host-type cells divided by the percentage of
remaining donor-type cells.
Statistical analyses
To assess statistical significance, Student’s t tests and paired t
tests were performed using SigmaPlot 2000 software (SPSS Inc.,
Chicago, Illinois). The Kaplan-Meier product limit method was
used to obtain the survival probability and the log-rank test was
applied to compare the survival curves. P,0.05 was considered
statistically significant.
Supporting Information
Figure S1 CD103 expression by CD8 T cells in the host
intestine (A) and spleen (B). CD8 T cells primed to A/J
alloantigens from either BALB/c-WT (WT) or BALB/c-CD103
KO donors were adoptively transferred into lethally irradiated A/J
recipient mice in combination with WT BMC. Data shown are 2-
dimensional plots of CD103 expression vs. CD8 expression for
gated CD8+ lymphocytes in the two compartments.
(TIF)
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Figure S2 CD103 expression is not required for CD8-
mediated cytotoxicity to host cells during GVHD.
Lethally-irradiated A/J mice received BMC plus alloantigen-
primed splenic CD8 T cells from either BALB/c-WT (WT) or
BALB/c-CD103 KO donors. At day 7 post-transplant recipients
mice received a mixture of WT (CFSElo) and A/J (CFSEhi)
splenocytes i,v,; 18 hrs later mice were bled and in vivo
cytotoxicity indices calculated. Data shown are cytotoxicity indices
in recipients of CD8 T cells from WT (n = 4) or KO (n = 4) donors
(mean 6 SEM).
(TIF)
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